Artivion reported second quarter 2026 results with revenue increasing 11% to $125.8 million compared to $113.0 million in the prior year period. The company posted a GAAP net loss of $(13.5) million, or $(0.28) per diluted share, while non-GAAP net income was $6.3 million, or $0.13 per diluted share. Adjusted EBITDA rose 7% to $26.4 million. Key operational milestones included the completion of the Endospan acquisition and U.S. FDA PMA approval for the AMDS Hybrid Prosthesis. Artivion reiterated its full-year 2026 revenue guidance of $480 to $496 million and adjusted EBITDA guidance of $92 to $99 million. The company operates in the medical device industry, developing solutions for cardiac and vascular surgery.